

Day 1	Public Health and Epidemiology				
07.00	Registration Level 8				
08.30 - 09:00	Opening Ceremony Room: Montreal Ballroom, Level 11 Chairs: Julie Bruneau, Marina Klein, and Jason Grebely				
08.30 - 08.45	Welcome to the Conference				
08.45 - 08.50	Community Opening				
08.50 - 09.00	Awards				
09.00 - 10.45	Session A: Public Health and Epidemiology Room: Montreal Ballroom, Level 11 Chairs: Margaret Hellard and Matthew Hickman				
09.00 - 09.20	The changing landscape of drug use globally: Implications for hepatitis C elimination Louisa Degenhardt, UNSW Sydney, Australia				
09.20 - 09.25	Questions & Discussion				
09.25 - 09.45	Global progress towards hepatitis C elimination: success and challenges Margaret Hellard, Burnet Institute, Australia				
09.45 - 10.00	The Scottish Experience: Reduction in the Population Prevalence of Chronic HCV among People Who Inject Drugs Associated with Major Scale-Up of Direct-Acting Antiviral Therapy in Community Drug Services: Real World Data Norah Palmateer, Glasgow Caledonian University, Glasgow				
10.00 - 10.10	The Georgian experience. Not just cure. The broader benefits of providing hepatitis C treatment in needle and syringe programs services Maia Butsashvili, Health Research Union, Georgia				
10.10 - 10.20	The Iceland experience. Getting the band together: The importance of bringing together government, hepatology, infectious diseases, drug and alcohol services and the prison sector to engage with people who inject drugs in hepatitis C care Sigurdur Olafsson, Landspítali University Hospital, Iceland				
10.20 - 10.30	Questions & Discussion				
10.30 - 10.45	Life and loss in the race to elimination: What does viral elimination potentiate and what does it leave behind? Kari Lancaster, Centre For Social Research In Health, UNSW, Australia				
10.45 - 11.15	Coffee Break and Poster Viewing Level 8				
11.15- 12.15	Session B: Mathematical Modelling to Inform Practice and Policy Room: Montreal Ballroom, Level 11 Chairs: Tim Rhodes and Kari Lancaster				
11.15 - 11.35	How can mathematical modelling be used to better inform research, practice and policy in hepatitis C and drug user health? Peter Vickerman, University of Bristol, United Kingdom				
11.35 - 12.15	Panel - Modelling Elimination: What Can Models Do? What Effects Do They Make? Moderator: Tim Rhodes, London School of Hygiene and Tropical Medicine, United Kingdom Panellists: Natasha Martin, University of California San Diego; Nick Scott, Burnet Institute, Australia; Homie Razavi, Centre for Disease Analysis, United States; Kari Lancaster, University of New South Wales, Australia; John Dillon, University of Dundee, United Kingdom; Tracy Swan, Consultant, United States; Niklas Luhmann, World Health Organisation, Switzerland				
12.15 - 14.00	Lunch & Poster Viewing Level 8				
12.45 - 13.45	Industry Sponsored Symposium: Working Together toward HCV Elimination in People Who Use Substances: A Multidisciplinary Approach Room: Fortifications, Level 9				
14.00 - 15.20	Session C: Progress towards hepatitis C elimination Room: Montreal A & B, Level 11 Chairs: Philip Bruggmann and Adelina Artenie	14.00 - 15.20	Session D: Ways to improve HCV testing, treatment and care Room: Montreal C & D, Level 11 Chairs: Mel Krajden and Lise Lafferty	14.00 - 15.20	Session E: Models of care to enhance engagement in care Room: Room: Fortifications, Level 9 Chairs: Marie-ève Goyer and Martin Käberg
14.00 - 14.15	How the elimination of a virus came to be: Modelling and the life of targets Tim Rhodes, UNSW, Australia	14.00 - 14.15	Task shifting in HCV testing and research: improving knowledge of HCV status through a peer outreach hepatitis c point of care project in Toronto, Canada Jennifer Broad, South Riverdale Community Health Centre, Canada	14.00 - 14.15	The Kombi Clinic – It's the end of the road for Hepatitis C Mary O'Flynn, Kombi Clinic, Australia
14 15 - 14.30	Recent opioid agonist therapy and hepatitis C virus treatment uptake among people who inject drugs with chronic hepatitis C infection in a population based data linkage study Sofia Bartlett, BC Centre For Disease Control, Canada	14 15 - 14.30	Maximising adherence to direct-acting antivirals among street-based and marginalised clients: The results of daily dosing Phillip Read, Kirketon Road Centre, Australia	14 15 - 14.30	Effective DAA HCV Treatment and Care Model Among People Who Inject Drugs in Most Hard-to-Reach Conflict Areas in Northern Myanmar Su Su Aung, Asian Harm Reduction Network, Myanmar
14.30 - 14.45	An intervention to improve HCV testing, linkage to care, and treatment among people who use drugs in Tehran, Iran: The ENHANCE study Maryam Alavi, The Kirby Institute, UNSW Sydney, Australia	14.30 - 14.45	Changes in attitudes, knowledge and everyday life throughout direct-acting antiviral treatment for hepatitis c: a longitudinal qualitative study Stelliana Goutzamanis, Burnet Institute, Australia	14.30 - 14.45	Addressing the HCV cascade of care in vulnerable populations with poor access to healthcare in Madrid through of a point of care in a one step Jorge Valencia, Harm reduction Unit "SMASD"; Subdirección General de Adicciones, Spain
14.45 - 14.50	The evolving hepatitis C care cascade in a real-world setting: results for the period 2003-2017 from Free Clinic Antwerp Catharina Mathei, Free Clinic Antwerp, Belgium	14.45 - 14.50	Factors that influence people who use drugs' experiences with direct-acting antiviral treatment for hepatitis c: a qualitative study in Vancouver, Canada Rod Knight, National Prisons Hepatitis Network, Australia	14.45 - 14.50	National Prisons Hepatitis Network - Facilitating enhanced infrastructure and scale-up of HCV treatment in Australian prisons: towards national elimination Yumi Sheehan, National Prisons Hepatitis Network, Australia

14.50 - 14.55	High uptake of direct-acting antiviral therapy for hepatitis C virus and reduction in population-level viremic prevalence: Progress toward achieving hepatitis C elimination among people who inject drugs in Australia Heather Valerio, The Kirby Institute, UNSW Sydney, Australia	14.50 - 14.55	Dispensing mode and hepatitis c direct acting antiviral treatment completion John Koo, Vancouver Coastal Health, Canada	14.50 - 14.55	Police are responsive to hepatitis C prevention: Police sensitization with a hepatitis C entry have proven to be more effective in Nairobi, Kenya Wangari Kimemia, Medecins Du Monde, Kenya
14.55 - 15.00	Early impact of direct-acting antivirals on chronic hepatitis C prevalence among people who inject drugs in England: Real world data, 2011-2017 Megan Bardsley, Public Health England, United Kingdom	14.55 - 15.00	HCV support groups: do they still have a role in the DAA era? Tianna Magel, Vancouver Infectious Diseases Centre, Canada	14.55 - 15.00	Establishing an Integrated Care Clinic for HCV-infected People Who Actively Inject Drugs (PWID) at a Harm Reduction Center in Washington, DC (ANCHOR Model) Rachel Silk, University Of Maryland, United States
15.00 - 15.05	Opportunities for engaging patients in care along the hepatitis C cascade of care Alisa Pedrana, Burnet Institute, Australia	15.00 - 15.05	Peers4wellness: indigenous model for supportive HCV and HIV care Sadeem Fayed, Simon Fraser University, Canada	15.00 - 15.05	Hepatitis C treatment integration with harm reduction services in Georgia: Preliminary findings Maia Butsashvili, Health Research Union, Georgia
15.05 - 15.10	A one-stop community-based approach for HCV screening, diagnosis and treatment among people who inject drugs in Iran: The Rostam study Samira Hosseini Hooshyar, The Kirby Institute, UNSW Sydney, Australia	15.05 - 15.10	A two-eyed seeing approach to wholistic healing and wellness for people with drug use experience Matthew Fischer, Indigenous Wellness Research Group, Canada	15.05 - 15.10	Good practices in health response to HCV in a harm reduction program Cláudia Pereira, Ares Do Pinhal, Portugal
15.10 - 15.15	Decreasing hepatitis C incidence and prevalence through enhancing HCV care and treatment among HIV co-infected individuals: The CO-EC study outcomes Joseph Doyle, Burnet Institute, Australia	15.10 - 15.15	Enhanced self-efficacy for HCV management among people participating an HCV education program focused on drug and alcohol and primary care settings Nikitah Habraken, Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine, Australia	15.10 - 15.15	Partnering with consumers: The development of a primary health care hepatitis C treatment model within a peer-based needle and syringe program John Lockwood, Kirketon Road Centre, Australia
15.15 - 15.20	Engaging drug using communities to scale up diagnosis and inform national HIV/HCV elimination efforts Annette Gaudino, Treatment Action Group, United States	15.15 - 15.20	Accessible care intervention for engaging people who inject illicit drugs in hepatitis C virus care: preliminary results from a randomized clinical trial Benjamin Eckhardt, New York University School Of Medicine, United States	15.15 - 15.20	A community-based approach to viral hepatitis in central Appalachia Jane Crowe, Knox Country Health Department, United States
15.20 - 16.15 Coffee Break & Poster Tour Level 8					
15.30 - 16.00	Poster Tour 1: Social Science Chair: Tim Rhodes	15.30 - 16.00	Poster Tour 2: Epidemiology & Public Health Chair:		
16.15 - 17.45	Session F: Prevention of Hepatitis C Room: Montreal A & B, Level 11 Chairs: Natasha Martin and Niklas Luhmann	16.15 - 17.45	Session G: Decolonizing hepatitis C treatment and research: Innovative approaches by and with Indigenous people Room: Montreal C & D, Level 11 Chairs: Alexandra King and Renée Masching	16.15 - 17.45	Session H: Addressing Barriers to Hepatitis Prevention and Care Room: Fortifications, Level 9 Chairs: Melisa Dickie and Mary Ellen Harrod
16.15 - 16.35	Hepatitis C reinfection among people who inject drugs: Should we worry? Havard Midgard, Oslo University Hospital, Norway	16.15 - 16.20	Territorial Acknowledgement /Welcome to Territory	16.15 - 16.35	Structural barriers in the delivery of services for people who use drugs Jose Queiroz, APDES, Portugal
		16.20 - 16.25	Opening Blessing Elder Sharon Jinkerson Brass, Key First Nation, Canada & Sadeem Fayed, Indigenous Wellness Research Group, Canada		
		16.25 - 16.35	Overview Alexandra King, University of Saskatchewan, Canada & Renée Masching, Canadian Aboriginal AIDS Network, Canada		
16.35 - 16.55	Opportunities and challenges for harm reduction and HCV prevention among people who use drugs: South African reflections Andrew Scheibe, TB HIV Care, South Africa	16.35 - 16.55	Developing new pathways of care in addiction services; a partnership between Onentokon Healing Lodge and the Centre hospitalier de l'Université de Montréal Arlette Ven Den Hende, Onentokon Healing Lodge, Canada & Stéphanie Marsan, Centre hospitalier de l'Université de Montréal, Canada	16.35 - 16.55	The critical role of peers in facilitating care for people who use drugs Jennifer Broad, South Riverdale Community Health Centre, Canada
16.55 - 17.15	What does the future hold for a hepatitis C vaccine? Naglaa Shoukry, Université de Montréal, Canada	16.55 - 17.15	Dried blood spots and disruptive innovation: Empowerment of Indigenous communities to address the colonial etiology of hepatitis C Anne Beck, Kitchenuhmaykoosib Inninuwug (Big Trout) First Nation, Canada & John Kim, National Laboratory for HIV Reference Services, Public Health Agency of Canada, Canada	16.55 - 17.15	How can knowledge translation be used to enhance the uptake of interventions in marginalized populations? Catherine Hankins, McGill University, Canada
17.15 - 17.45	Questions & Discussion	17.15 - 17.35	Healing through research: Indigenous research methodologies in the substance use and hepatitis C space Elder Sharon Jinkerson Brass, Key First Nation, Canada & Sadeem Fayed, Indigenous Wellness Research Group, Canada	17.15 - 17.45	Questions & Discussion
		17.35 - 17.45	Questions & Discussion		
17.45 - 19.00 Welcome Reception & Poster Viewing					

Day 2							
07.30							
Registration							
08.00 - 08.45							
Industry Sponsored Symposium: A step closer to achieving HCV elimination in substance users							
Room: Fortifications, Level 9							
09.00 - 10.45							
Session I: Moving from clinical trials to the real-world							
Room: Montreal Ballroom, Level 11							
Chairs: Shruti Mehta and Gregory Dore							
09:00 - 09:20							
Overcoming barriers to integrating hepatitis C testing, linkage to care and treatment into existing services: success stories from low and middle income countries							
Sunil Solomon, Johns Hopkins University, United States							
09:20 - 09:40							
Moving from clinical trials to the real world: Effectiveness research for hepatitis c							
Lisa R. Metsch, Columbia University, United States							
09:40 - 10:00							
Skype Presentation: Supporting enhanced efforts to address hepatitis C and health for people who use drugs through strong government leadership							
Ricardo Baptiste Leite, UNITE, Portugal							
10.00 - 10.15							
Questions & Discussion							
10.15 - 10.30							
Australia will need to increase testing to achieve hepatitis C elimination							
Nick Scott, Burnet Institute, Australia							
10.30 - 10.45							
Barriers and facilitators to engaging in HCV management and DAA therapy among general practitioners and drug and alcohol specialists - The practitioner experience							
Alison Marshall, The Kirby Institute, UNSW Sydney, Australia							
10.45 - 11.15							
Coffee Break & Poster Viewing							
Level 8							
11.15 - 12.15							
Session K: Hepatitis C risk and prevention		11.15 - 12.15		Session L: Enhancing hepatitis C testing and linkage to care		11.15 - 12.15	
Room: Montreal A & B, Level 11				Room: Montreal C & D, Level 11		Session J Workshop 1: Peers facilitating access to their criminalized communities improving the hep c cascade of care: How to meaningfully engage and involve people with lived experience (PWLE) in your programs	
Chairs: Hannah Fraser and Behzad Hajarizadeh				Chairs: Valerie Martel-Laferriere and Joshua Barocas		Room: Fortifications, Level 9	
						Chairs: Jennifer Broad & Jude Byrne	
11.15 - 11.30		11.15 - 11.30		11.15 - 11.30		11.15 - 12.15	
Association between short-term housing patterns and hepatitis c acquisition: findings from a cohort of people who inject drugs in Montréal, Canada		Making Oraquick quicker: A hepatitis C point-of-care test reduced to five minutes for viremic individuals		Time to detection of hepatitis C virus infection with the Xpert HCV Viral Load finger-stick point-of-care assay: Facilitating a more rapid time to diagnosis		This session will provide an opportunity to meet, network and collaborate with other service providers, program planners, community members and researchers who have a focus on front-line services and programs. You'll engage in facilitated discussions on approaches in four settings: prisons, harm reduction and needle-syringe programs, addiction medicine and opioid substitution therapy, and mobile and community-based.	
Emmanuel Fortier, CHUM Research Centre, Canada		Aaron Vanderhoff, Viral Hepatitis Care Network, Canada		Jason Grebely, The Kirby Institute, UNSW Sydney, Australia		This session is presented by INHSU and CATIE. CATIE is Canada's source for HIV and hepatitis C information	
11.30 - 11.45		11.30 - 11.45		11.45 - 12.00			
Diversity of detention patterns among people who inject drugs and the associated risk with incident hepatitis c virus (HCV) infection: Implications for HCV prevention		Targeted testing pathways improve hepatitis C diagnosis rates		Cost-effectiveness of hepatitis c virus screening and treatment with direct-acting antivirals in people who inject drugs in Nairobi, Kenya			
Andreea Adelina Arteni, University Of Montréal, Canada		Emma Robinson, University Of Dundee, United Kingdom		Jack Stone, University Of Bristol, United Kingdom			
11.45 - 12.00		12.00 - 12.05		12.05 - 12.10			
Modelling the impact of prevention and treatment interventions for people who inject drugs in Dar es Salaam, Tanzania		HIV and HCV among people who inject drugs in Ukraine: a stabilization or a calm before the storm?		The cost-effectiveness of an HCV outreach intervention for at-risk populations in London, UK			
Hannah Fraser, University of Bristol, United Kingdom		Marina Kornilova, Alliance For Public Health, Ukraine		Zoe Ward, University Of Bristol, United Kingdom			
12.00 - 12.05		12.05 - 12.10		12.10 - 12.15			
HCV among people who inject drugs in France: Acting on risk environment in an evolving crisis		The Brazilian syndemics of crack use, HIV and HCV		Using a systems-thinking approach to elucidate programme theory underpinning the effectiveness of Superdot-C: a pharmacy-led test and treat pathway for PWIDS			
Marie Jauffret-Roustide, Inserm, France		Alexandra Almeida, SDSU, United States		Andrew Radley, NHS Tayside, United Kingdom			
12.10 - 12.15		12.15 - 14.00					
Lunch and Poster Viewing		Level 8					
12.45 - 13.45							
Industry Sponsored Symposium: Transforming HCV care: the power of collaboration							
Room: Fortifications, Level 9							
14.00 - 15.00							
Session M: Hepatitis prevention, treatment, and care in prisons		14.00 - 15.00		Session N: Enhancing hepatitis C treatment		14.00 - 15.00	
Room: Montreal A & B, Level 11				Room: Montreal C & D, Level 11		Session O: Models of care: targeted interventions in various settings	
Chairs: Andrew Lloyd and Lisa Barrett				Chairs: Brian Conway and Anne Øvrehus		Room: Fortifications, Level 9	
						Chairs: Alexandra King and Shashi Kapadia	
14.00 - 14.15		14.00 - 14.15		14.00 - 14.15		14.00 - 14.15	
The hepatitis c virus (HCV) cascade of care in the New York City (NYC) jail system		Nurse-led, community-based hepatitis c treatment is feasible and effective among people who inject drugs and their injecting network: the HCV treatment and prevention (TAP) study		Approaches to providing hepatitis C viremia testing to people who inject drugs in Georgia, Head Start (Hepatitis Elimination Through Access to Diagnostics) Georgia		Peer-led approach on treatment of Hepatitis C	
Justin Chan, Correctional Health Services, NYC Health + Hospitals, United States		Joseph Doyle, Burnet Institute, Australia		Maia Japaridze, FIND, Switzerland		Manasseh Muriithi, MDM-france, Kenya	
14.15 - 14.30		14.15 - 14.30		14.15 - 14.30		14.15 - 14.30	
Injecting culture following prison-wide hepatitis C treatment scale-up: negotiating risk after cure		Comparing trial designs for HCV treatment as prevention: An empirical evaluation		Increasing access to addiction services for Indigenous communities in Quebec: An integrated model of care between Onen'to:kon Healing Lodge,		A peer-based support-model for HCV treatment for PWID, integrated into a public healthcare facility in Hanoi, Vietnam	
Lise Lafferty, UNSW Sydney, Australia		Natasha Martin, University Of California San Diego, United States		Stephanie Marsan, Centre hospitalier de l'Université De Montréal, Canada		Mathilde Laval, Medecins Du Monde, France	

14.30 - 14.45	Set up to fail: the post-release experience of prisoners with a history of injection drug use Sophia Schroeder, Burnet Institute, Australia	14.30 - 14.45	Promise and pharmaceuticalisation in the era of direct-acting antivirals Jake Rance, Centre For Social Research In Health, Australia	14.30 - 14.45	Micro-elimination of Hepatitis C among people who use drugs in an Indigenous community in Saskatchewan Canada Noreen Reed, Ahtahkakoop Health Clinic, Canada	14.30 - 14.45	The Hepatitis Bus – A Norwegian drug user initiative Ronny Bjørnstad, proLAR Nett, Norway
14.45 - 14.50	Perceived barriers to and facilitators of HCV treatment uptake in jail and linkage to HCV care after incarceration: a qualitative study Matthew Akiyama, Montefiore Medical Center, United States	14.45 - 14.50	Real-world outcomes in Patients with Chronic Hepatitis C Virus Infection with Opioid Substitution Therapy, Mental Disorders, or Alcohol use Disorder Treated with Glecaprevir/Pibrentasvir: Data From The German Hepatitis C-Registry Stefan Christensen, CIM Münster, Germany	14.45 - 14.50	Successful treatment of hepatitis c among people who inject drugs in Nairobi, Kenya Gladys Ngwei, Medecins Du Monde, Kenya	14.45 - 14.50	Community-based organization spearheads efforts to translate HCV interventions to prison settings in Jakarta Caroline Thomas, Koalisi Satu Hati, Indonesia
14.50 - 14.55	Enhancing linkage to hepatitis C care upon release from Canadian provincial prisons: the population-level impact on hepatitis C transmission among people who inject drugs in Montréal Arnaud Godin, McGill University, Canada	14.50 - 14.55	Real-world outcomes from people who use drugs with chronic hepatitis C virus infection treated with glecaprevir/pibrentasvir: A pooled analysis of post-marketing observational studies Juliette Foucher, Hopital de Haut Leveque, France	14.50 - 14.55	Pharmacist-led HCV screening, diagnosis and treatment in an opioid substitution therapy outpatient pharmacy Colter Young, Shoppers Drug Mart, Canada	14.50 - 14.55	Can patient groups lead diagnosis and treatment in prisons of resource limited settings? We are doing it! Nalinikanta Rajkumar, Community Network For Empowerment (CoNE), India
14.55 - 15.00	Disparities in Hepatitis C virus (HCV) care across Quebec's provincial prisons: Implications for HCV micro-elimination Nadine Kronfli, McGill University, Canada	14.55 - 15.00	Actively injecting PWID who use stimulants can be successfully treated for HCV infection Sigurdur Olafsson, Landspítali University Hospital, Iceland	14.55 - 15.00	Evaluation of the Xpert HCV Viral Load Fingerstick assay in the harm reduction setting in Catalonia, Spain Verónica Saludes, Germans Trias I Pujol University Hospital Research Institute (Igt), Spain	14.55 - 15.00	Methadone maintenance treatment program (MMTP) in Nepal: Role of user-led organizations in engaging and empowering MMTP patients Ranjit Tiwari, National User Network of Nepal, Nepal
15.00 - 15.45	Coffee Break and Poster Tour Level 8						
15.10 - 15.40	Poster Tour 3: Clinical			15.10 - 15.40	Poster Tour 4: Models of Care Chair: John Dillon		
15:45 - 17:15	Session P: Prisons Room: Montreal A & B, Level 11 Chairs: Nadine Kronfli and Matthew Akiyama	15:45 - 17:15	Session Q: Strategies to enhance testing and diagnosis Room: Montreal C & D, Level 11 Chairs: Jason Grebely and Karine Lacombe	15:45 - 17:15	Session R: Neglected but not forgotten: innovative ways to engage women who use drugs into HCV care (supported by IAS) Room: Fortifications, Level 9 Chairs: Marina Klein and Judy Chang		
15.45 - 16.05	Tackling prisoner health via an upstream public health approach Prem Thurairajah, Changi General Hospital, Singapore	15.45 - 16.05	Diagnostics for hepatitis C: Where do we stand and what lies ahead? Sonjelle Shilton, The Foundation for Innovative New Diagnostics, Switzerland	15.45 - 15.50	Myanmar Video Médecins du Monde		
16.05 - 16.25	Project ECHO as a model for hepatitis care in the prisons Kara Thornton, University of New Mexico, United States	16.05 - 16.25	Expanding hepatitis C testing and diagnosis for people who inject drugs in low- and middle-income countries: Successes and challenges Ernst Wisse, Medecins Du Monde, France	15.50 - 16.10	Hepatitis C Screening and Management Among Women Who Inject Drugs. A Case of Nairobi County, Kenya Gladys Mwende Ngwe, Medecins du Monde, Kenya		
16.25 - 16.45	Hepatitis C testing and treatment in correctional centers in the United States Anne Spaulding, Emory University, United States	16.25 - 16.45	How can we facilitate the implementation of novel testing strategies and diagnosis beyond the laboratory? Philip Cunningham, St Vincent's Hospital, Australia	16.10 - 16.30	Gender-based approaches to harm reduction and anti-violence programs for women who use drugs in Ukraine Valta Parkhomenko, Club Eney, Ukraine		
16.45 - 17.15	Questions & Discussion	16.45 - 17.15	Questions & Discussion	16.30 - 16.50	Sheway: An interdisciplinary response to improving outcomes for pregnant women who use substances Janine Hardial, Sheway Clinic, Vancouver, Canada		
19:00 - 23:00	Conference Dinner						

Day 3	Moving beyond hepatitis C
09.00	Registration
09.00 - 09.30	Light Breakfast and Poster Viewing Level 8
09.30 - 11.00	Session S: Hepatitis C and Health for People who Use Drugs Room: Montreal Ballroom, Level 11 Chairs: Naveed Janiua and Laurence Marsillan
09.30 - 09.50	Beyond Hepatitis C: Improving the health and lives of people who use drugs Mark Tyndall, University of British Columbia, Canada
09.50 - 10.10	Health economics of substance use and hepatitis C: Informing practice and policy Bruce Schackman, Weill Cornell Medical College, United States
10.10 - 10.30	Questions & Discussion
10.30 - 10.45	Comparing adherence to once-daily and twice daily DAA therapy among people with recent injection drug use or current opioid substitution therapy: The SIMPLIFY and D3FEAT studies Evan Cunningham, The Kirby Institute, UNSW Sydney, Australia
10.45 - 11.00	Clinical effectiveness of pharmacy-led versus conventionally delivered antiviral treatment for hepatitis C in patients receiving opioid substitution therapy: A pragmatic cluster randomised trial Andrew Radley, NHS Tayside, United Kingdom
11.00 - 11.30	Coffee Break and Poster Viewing Level 8
11.30 - 12.00	Session T: 'Connecting with Care' – A Film Preview of Models of Care from Canada and beyond' Room: Montreal Ballroom, Level 11 Chairs: Conor Ashleigh
11.30 - 11.35	Introduction Conor Ashleigh, Visual Story Teller, Australia
11.35 - 11.40	The ENHANCE project, an intervention to increase hepatitis C diagnosis and treatment in Tehran, Iran Maryam Alavi, ENHANCE, Australia
11.40 - 11.45	Montreal's many models of care Julie Bruneau, CRISM, Canada; Hugo Bissonnet, Centre Sida Amitie, Canada; Martin Page, Dopamine, Canada
11.45 - 11.50	A Saskatchewan Story, Athahkakoop's Indigenous Model of Care Noreen Reed, Athahkakoop Clinic, Canada; Jennifer Ahenakew, Athahkakoop, Canada; Stuart Skinner, University Of Saskatchewan, Canada
11.50 - 12.00	Questions & Discussion
12.00 - 13.45	Lunch & Poster Viewing Level 8
12.30 - 13.30	INHSU GAM Room: Fortifications, Level 9

13.45 - 14.45	Session U: Hepatitis C reinfection Room: Montreal A & B, Level 11 Chairs: Charlotte Laniece and Phillip Read	13.45 - 14.45	Session V: Beyond hepatitis C Room: Montreal C & D, Level 11 Chairs: Sione Crawford and Sarah Larney	13.45 - 14.45	Session W: Models of care to enhance engagement in care Room: Fortifications, Level 9 Chairs: Lynn Taylor and Chris Fraser
13.45 - 14.00	Hepatitis C Virus Reinfection after Successful Treatment with Direct-Acting Antiviral Therapy in Canada Naveed Janjua, BC Centre For Disease Control, Canada	13.45 - 14.00	Operationalizing the risk environment: spatial distribution of people who inject drugs and hotspots of social injecting activity in Montreal, Canada Nanor Minoyan, University of Montréal CRCHUM, Canada	13.45 - 14.00	Community centric HCV testing and treatment for PWID in Manipur, India - The Head Start Project Babu Entroor Ramachandran, FIND, India
14.00 - 14.15	Risk of HCV reinfection and associated patterns of behaviour among men who inject drugs or who have sex with men in Canada Brendan Jacka, Research Institute, Centre hospitalier de l'Université de Montréal (CHUM), Canada	14.00 - 14.15	The impact of opioid agonist treatment on mortality among people who inject drugs: A 3 site modelling analysis Jack Stone, University Of Bristol, United Kingdom	14.00 - 14.15	'Get Tested LeEDs': (Re)-diagnosing and (re)-engaging PWID with blood borne viruses (BBV) in an urban emergency department Emma Page, Leeds Teaching Hospitals Trust, United Kingdom
14.15 - 14.30	Hepatitis C virus reinfection following antiviral treatment among people who use or inject drugs: a systematic review and meta-analysis Behzad Hajari, The Kirby Institute, UNSW Sydney, Australia	14.15 - 14.30	Growing old with drugs. Preliminary results from a qualitative study on the aging process of drug users in opioid substitution treatment Margheria Luciani, University Of Applied Sciences Of Southern Switzerland, Switzerland	14.15 - 14.30	Treating people where they are: Nurse-led hepatitis C (HCV) micro-elimination project for networks of people with recent injecting drug use in Victoria, Canada Karen Lundgren, Cool Aid Community Health Centre, Canada
14.30 - 14.35	Drug use and reinfection during and following HCV treatment with elbasvir/grazoprevir (EBV/GZR) among patients receiving opioid agonist therapy: Final results from the CO-STAR study Gregory Dore, The Kirby Institute, UNSW Sydney, Australia	14.30 - 14.35	Impacts of Hepatitis C Virus Infection Treatment for Patients in Treatment for Opioid Use Disorder Robert Heimer, Yale University School of Public Health, United States	14.30 - 14.35	A cost-benefit analysis of primary versus hospital-based specialist care for direct acting antiviral hepatitis C treatment Nick Scott, Burnet Institute, Australia
14.35 - 14.40	Low rate of reinfection among a cohort of people who inject drugs successfully treated for hepatitis C virus infection within a multidisciplinary program Brian Conway, Vancouver Infectious Disease Centre, Canada	14.35 - 14.40	An international systematic review of methadone and buprenorphine doses used in the treatment of opioid use disorder Sarah Larney, National Drug And Alcohol Research Centre, UNSW Sydney, Australia	14.35 - 14.40	Engaging mother-infant dyads in hepatitis C care through perinatal pediatric infectious diseases consultation Rachel Epstein, Boston Medical Center, United States
14.40 - 14.45	Rare HCV Re-infection after DAA Treatment in an Integrated All-Under-One-Roof Care Setting Claudia Bernardini, ARUD, Switzerland	14.40 - 14.45	High Rates of Opioid Overdose and Witnessed Overdose in PWID Receiving HCV Treatment: Data from the ANCHOR Study Elana Rosenthal, University Of Maryland School Of Medicine, United States	14.40 - 14.45	Removing health insurance barriers and incorporating harm reduction with a physician - nurse - pharmacist team, to optimize hepatitis c virus (HCV) treatment in a U.S. co-located HCV/methadone maintenance program Jackie Habchi, Codac Behavioral Health, United States
14.45 - 15.15	Coffee Break and Poster Viewing	15.15 - 16.30	Session Y: How do we move forward policies on hepatitis C and drug use? Room: Montreal C & D, Level 11 Chairs: Jeffrey Lazarus and Annette Gaudino	15.15 - 16.30	Session Z: The critical role of the nurse for integrating health care for people who use drugs Room: Fortifications, Level 9 Chairs: Lesley Gallagher and Donna Zukowski
15.15 - 15.35	Emerging trends in stimulant use and the impact on hepatitis C Francisco Inacio Bastos, Oswaldo Cruz Foundation, Brazil	15.15 - 15.35	Policies to enhance access to hepatitis C prevention and treatment for people who use drugs Niklas Luhmann, World Health Organisation, Switzerland	15.15 - 15.25	Easy Access Within the Clinic and Corrections Janet Catt, Kings College Hospital NHS Foundation Trust, United Kingdom
15.35 - 15.55	Emerging Trends in alcohol and the impact on hepatitis C Jurgen Rehm, Centre for Addiction and Mental Health, Canada	15.35 - 15.55	Taking stock of a decade of drug policy: Where have we come and where to next? Marie Nougier, International Drug Policy Consortium, Country	15.25 - 15.35	Collaborating Within the Addiction Clinic Sidsel Sejr, KABS, Glostrup Kommune, Denmark
15.55 - 16.15	Emerging Trends in mental health and the impact on hepatitis C Didier Jutras-Aswad, Canadian Research Initiative in Substance Misuse (CRISM), Canada	15.55 - 16.15	Market dynamics and the hepatitis C response: Facilitating policy decisions to improve affordable, equitable access to treatment Sean Regan, Clinton Health Access Initiative, United States	15.35 - 15.45	Treat and Teach - Outreach to Indigenous Communities Lesley Gallagher, Saskatchewan Infectious Disease Care Network (SIDCN), Canada
16.15 - 16.30	Questions & Discussion	16.15 - 16.30	Questions & Discussion	15.45 - 15.55	The Independent Nurse Working as a Physician Delegate Jan Tait, Ninewells Hospital Dundee, United Kingdom
16.30 - 16.40	Room Movement			15.55 - 16.05	Managing HCV Elimination Heidi Friðriksdóttir, Landspítali University Hospital, Iceland
16.40 - 17.30	Conference Closing Room: Montreal Ballroom, Level 11 Chairs: Julie Bruneau and Marina Klein			16.05 - 16.15	Confidence to treat HCV through Mentorship Manasseh Murage, Médecins du Monde, Kenya
16.40 - 16.50	Community Rapporteur			16.15 - 16.30	Questions & Discussion
16.50 - 17.00	Policy & Epidemiology Rapporteur Jack Stone, University of Bristol, United Kingdom				
17.00 - 17.10	Linkage to Care & Treatment Rapporteur Tracy Swan, Consultant United States				
17.10 - 17.20	Models of Care Rapporteur John Dillon, University of Dundee, Scotland				
17.20 - 17.30	Conference Closing and Introduction of Upcoming Conference				